immunotherapy
CuraCell granted approval for trial of new therapy for metastatic cancers
August 13, 2025Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer
Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
August 4, 2025CERo therapeutics, Cancer, T cell, immunotherapy
The current forms of immunotherapy, how T cell therapy works and what the future holds
T-cell therapy – the evolution of cancer treatments
July 7, 2025CERo therapeutics, Cancer, T cell, immunotherapy
The current forms of immunotherapy, how T cell therapy works and what the future holds
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
May 15, 2025Medical Communications, Sales and Marketing Corporate, European Innovation Council (EIC), Immunology, Neogap Therapeutics, US pharma market, biotech, immunotherapy
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme for Healthcare and Life Sciences …
Neogap chosen for Innovate Nordics 2025 Acceleration Programme
May 1, 2025Research and Development Innovate Nordics, Neogap Therapeutics, Oncology, biotech, funding programme, immunotherapy
Swedish biotech company Neogap Therapeutics has been chosen to join Innovate Nordics’ 2025 acceleration programme, a prestigious initiative designed to …
Dual immunotherapy for bowel cancer now available under NHS
April 23, 2025Research and Development Bristol Myer Squibb, MHRA, NICE, Oncology, bowel cancer, colorectal cancer, immunotherapy
Dual immunotherapy, a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), has been granted extension in the UK by the Medicines …
Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment
April 4, 2025Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo
Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …
University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients
January 14, 2025Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients
The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …
AC Immune’s pTau-targeting immunotherapy awarded Fast Track designation by FDA
July 26, 2024Research and Development AC Immune, Alzheimer's disease, Neurology, clinical trials, fast track designation, immunotherapy, tau protein
Clinical-stage biopharmaceutical company AC Immune announced that the US Food and Drug Administration (FDA) has granted its Alzheimer’s disease (AD) …
Prostate Cancer ‘super responders’ could live for two more years on Keytruda
November 28, 2019Research and Development Cancer, immunotherapy, keytruda, oncology, prostate cancer
Men with advanced prostate cancer, who have exhausted all treatment options, could use the immunotherapy Keytruda (pembrolizumab) to live for …
Roche’s Tecentriq combo outclasses Nexavar in unresectable hepatocellular carcinoma
November 25, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
Roche has revealed new Phase 3 data for its immunotherapy drug Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
Roche’s Tecentriq/Avastin combo smashes endpoints at Phase 3 in unresectable hepatocellular carcinoma
October 21, 2019Research and Development, Sales and Marketing Cancer, Roche, immunotherapy, pharma, tecentriq
New Phase 3 data has emerged demonstrating the efficacy of Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) in the …
BMS unveils strong five-year efficacy data for Opdivo in lung cancer
September 11, 2019Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …
Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies
August 29, 2019Research and Development Cancer, Celgene, immatics, immunotherapy, pharma
Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …
Scientists use duoCAR-T therapy to fight HIV
August 9, 2019Medical Communications AIDS, CAR-T therapy, HIV, health, immunotherapy, pharma
Researchers from the University of Pittsburgh, working with the biotech Lentigen, have found that an advanced form of CAR-T therapy …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
